Trial · NCT00385580
Trial comparisons13
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 13 of 13
Download this page as JSON| Comparison | Source |
|---|---|
| Dasatinib 100 mg Once Daily (QD) vs Dasatinib 100 mg or 70 mg Twice Daily (BID): Number of Participants With Disease Progression | Trial comparisons |
| Dasatinib 100 mg Once Daily (QD) vs Dasatinib 100 mg or 70 mg Twice Daily (BID): Number of Participants With CR or PR | Trial comparisons |
| Dasatinib 100 mg Once Daily (QD) vs Dasatinib 100 mg or 70 mg Twice Daily (BID): Number of Participants With Abnormal Lactate Dehydrogenase (LD) | Trial comparisons |
| Dasatinib 100 mg Once Daily (QD) vs Dasatinib 100 mg or 70 mg Twice Daily (BID): Number of Participants With Decrease in PSA Velocity | Trial comparisons |
| Dasatinib 100 mg Once Daily (QD) vs Dasatinib 100 mg or 70 mg Twice Daily (BID): Number of Participants With CR, PR or SD | Trial comparisons |
| Dasatinib 100 mg Once Daily (QD) vs Dasatinib 100 mg or 70 mg Twice Daily (BID): Number of Participants With Increase in PSA Doubling Time | Trial comparisons |
| Dasatinib 100 mg Once Daily (QD) vs Dasatinib 100 mg or 70 mg Twice Daily (BID): Number of Participants With BAP Response | Trial comparisons |
| Dasatinib 100 mg Once Daily (QD) vs Dasatinib 100 mg or 70 mg Twice Daily (BID): Number of Participants With Decrease in PSA Log Slope | Trial comparisons |
| Dasatinib 100 mg Once Daily (QD) vs Dasatinib 100 mg or 70 mg Twice Daily (BID): Number of Participants With a Confirmed Improved Bone Scan | Trial comparisons |
| Dasatinib 100 mg Once Daily (QD) vs Dasatinib 100 mg or 70 mg Twice Daily (BID): Number of Participants With QTc Prolongation | Trial comparisons |
| Dasatinib 100 mg Once Daily (QD) vs Dasatinib 100 mg or 70 mg Twice Daily (BID): Number of Participants With a Response | Trial comparisons |
| Dasatinib 100 mg Once Daily (QD) vs Dasatinib 100 mg or 70 mg Twice Daily (BID): Number of Participants With a Decrease in PSA by at Least 50% From Baseline | Trial comparisons |
| Dasatinib 100 mg Once Daily (QD) vs Dasatinib 100 mg or 70 mg Twice Daily (BID): Number of Participants With a uNTx Response | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00385580/comparisons